Cancer Database Query Results

Scientific Papers found: Click to Expand⟱
4822- ASTX,  Rad,    Astaxanthin Synergizes with Ionizing Radiation (IR) in Oral Squamous Cell Carcinoma (OSCC)
tumCV↓, selectivity↑, RadioS↑, GPx4↓, Ferroptosis↑,
4821- ASTX,    Astaxanthin Reduces Stemness Markers in BT20 and T47D Breast Cancer Stem Cells by Inhibiting Expression of Pontin and Mutant p53
- in-vitro, BC, SkBr3 - in-vitro, BC, BT20 - in-vitro, BC, T47D
Apoptosis↑, CSCs↓, OCT4↓, Nanog↓, TumCP↓,
4820- ASTX,    Astaxanthin suppresses the malignant behaviors of nasopharyngeal carcinoma cells by blocking PI3K/AKT and NF-κB pathways via miR-29a-3p
- in-vitro, NPC, NA
TumCP↓, TumCI↓, Apoptosis↑, TumCCA↑, cycD1/CCND1↓, Bcl-2↓, P21↑, BAX↑, PI3K↓, Akt↓, NF-kB↓, miR-29b↑,
4819- ASTX,    Astaxanthin Induces Apoptosis in MCF-7 Cells through a p53-Dependent Pathway
- in-vitro, BC, MCF7
antiOx↑, AntiTum↑, TumCD↑, P53↑, P21↑, Apoptosis↑, Dose↝, Casp3↑,
4818- ASTX,  MEL,    Effect of astaxanthin and melatonin on cell viability and DNA damage in human breast cancer cell lines
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, T47D - in-vitro, Nor, MCF10
TumCD↑, DNAdam↑, *antiOx↑, *AntiTum↑, Inflam↓, tumCV↓, Bcl-2↓, Apoptosis↓, selectivity↑, eff↑, Dose↓,
4817- ASTX,    Low Dose Astaxanthin Treatments Trigger the Hormesis of Human Astroglioma Cells by Up-Regulating the Cyclin-Dependent Kinase and Down-Regulated the Tumor Suppressor Protein P53
- in-vitro, GBM, U251
Dose⇅, ROS∅, SOD↑, CDK1↑, P53↓, TumCP⇅, ROS↑,
4816- ASTX,    Potent carotenoid astaxanthin expands the anti-cancer activity of cisplatin in human prostate cancer cells
- in-vitro, Pca, NA
*antiOx↑, *Inflam↓, ChemoSen↑, E-cadherin↑, N-cadherin↓, VEGF↓, cMyc↓, PSA↓, cl‑Casp3↑, PARP1↑,
4815- ASTX,    The Promising Effects of Astaxanthin on Lung Diseases
- Review, Var, NA
Dose↑, *BioAv↝, *BioAv↝, *antiOx↑, *NRF2↑, *ERK↓,
4804- ASTX,    Astaxanthin in cancer therapy and prevention (Review)
- Review, Var, NA - Review, AD, NA
*antiOx↑, *Inflam↓, ChemoSen⇅, chemoP↑, BioAv↑, TumCP↑, ROS⇅, Apoptosis↑, PI3K↑, Akt↑, GSK‐3β↑, NRF2↑, AntiCan↑, *neuroP↑, eff↑, AntiTum↑,
4813- ASTX,    Astaxanthin Prevents Oxidative Damage and Cell Apoptosis Under Oxidative Stress Involving the Restoration of Mitochondrial Function
- in-vitro, AD, NA
*antiOx↑, *Apoptosis↓, *AntiTum↑, *ROS↓, *MMP↑, *neuroP↑,
4812- ASTX,    Astaxanthin suppresses the metastasis of colon cancer by inhibiting the MYC-mediated downregulation of microRNA-29a-3p and microRNA-200a
- in-vitro, CRC, HCT116
miR-29b↑, miR-200b↑, MMP2↓, Zeb1↓, EMT↓, Apoptosis↑, ERK↓, MAPK↓, PI3K↓, Akt↓, MMPs↓, TumMeta↓,
4811- ASTX,    Astaxanthin reduces MMP expressions, suppresses cancer cell migrations, and triggers apoptotic caspases of in vitro and in vivo models in melanoma
- vitro+vivo, Melanoma, A375 - vitro+vivo, Melanoma, A2058
ROS↓, MMPs↓, TumCMig↓, TumMeta↓, TumCCA↑, antiOx↑, MMP1↓, MMP2↓, MMP9↓,
4810- ASTX,    Effects of Astaxanthin on the Proliferation and Migration of Breast Cancer Cells In Vitro
- in-vitro, BC, MDA-MB-231 - in-vitro, Nor, MCF10
TumCP↓, TumCMig↓, selectivity↑, *BDNF↑, *ROS↓, *TNF-α↓, *IL6↓, *IFN-γ↓, *NF-kB↓, BAX⇅, Bcl-2↓, *antiOx↑, radioP↑, ChemoSen↑,
4809- ASTX,    Astaxanthin Inhibits Proliferation of Human Gastric Cancer Cell Lines by Interrupting Cell Cycle Progression
- in-vitro, GC, AGS - in-vitro, GC, MKN45
tumCV↓, TumCP↓, TumCCA↑, p‑ERK↓, p27/CDKN1B↑, cycD1/CCND1↓, CDK4↓,
4808- ASTX,    Anti-Tumor Effects of Astaxanthin by Inhibition of the Expression of STAT3 in Prostate Cancer
- in-vitro, Pca, DU145 - in-vivo, NA, NA
TumCP↓, STAT3↓, Apoptosis↑, TumCMig↓, TumCI↓,
4807- ASTX,    An overview of the anticancer activity of astaxanthin and the associated cellular and molecular mechanisms
- Review, Var, NA
*antiOx↑, *neuroP↑, AntiCan↑, TumCG↓, TumCD↑, TumCMig↓, ChemoSen↑, chemoP↑, *BioAv↓, TumCP↓, TumCCA↑, Apoptosis↑, BioAv↑,
4806- ASTX,    Astaxanthin's Impact on Colorectal Cancer: Examining Apoptosis, Antioxidant Enzymes, and Gene Expression
- in-vitro, CRC, HCT116
BAX↑, Casp3↑, Apoptosis↑, Bcl-2↓, MDA↓, ROS↓, SOD↑, Catalase↑, GPx↑, antiOx↑, TumCG↓, TumCP↓,
4805- ASTX,    Astaxanthin promotes apoptosis by suppressing growth signaling pathways in HT-29 colorectal cancer cells
- in-vitro, Colon, HT29
TumCP↓, Casp3↑, EGFR↓, HER2/EBBR2↓, ERK↓, Apoptosis↑,
5426- ASTX,  Cisplatin,    Astaxanthin Prevents a Decrease of Hemopoietic Activity in Head and Neck Cancer Patients Receiving Cisplatin Chemotherapy (Randomized Controlled Trial)
- Trial, HNSCC, NA
ROS↓, SOD↑, MDA↓, eff↑,
5427- ASTX,    Astaxanthin and Cancer Chemoprevention
- Review, Var, NA
chemoP↑, AntiCan↑, chemoPv↑, Risk↓, lipid-P↓, Pain↓, BioAv↑, Dose↝,
5417- ASTX,    Comparative Pharmacokinetic Study of Standard Astaxanthin and its Micellar Formulation in Healthy Male Volunteers
- Study, Nor, NA
*antiOx↑, *BioAv↓, *Dose↝, *BioAv↑,
5418- ASTX,    Astaxanthin supplementation mildly reduced oxidative stress and inflammation biomarkers: a systematic review and meta-analysis of randomized controlled trials
- Review, Nor, NA
*MDA↓, *SOD↑, *IL6↓, *ROS↓, *Inflam↓,
5419- ASTX,    Astaxanthin and other Nutrients from Haematococcus pluvialis—Multifunctional Applications
- Review, Nor, NA
*antiOx↑, *Inflam↓, *AntiDiabetic↓, AntiCan↑, *lipid-P↓, TumCP↓, Apoptosis↑, TumCCA↑, *SOD↑, *PGE2↓, *NO↓, *IL8↓, *IFN-γ↓, *cardioP↑, *NF-kB↓, *TNF-α↓, *BioAv↑,
5420- ASTX,    A New Tailored Nanodroplet Carrier of Astaxanthin Can Improve Its Pharmacokinetic Profile and Antioxidant and Anti-Inflammatory Efficacies
- in-vivo, Nor, NA
*eff↑, *SOD↑, *BioAv↑,
5421- ASTX,    Astaxanthin Inhibits PC-3 Xenograft Prostate Tumor Growth in Nude Mice
- in-vivo, Pca, NA
TumCG↑, Ki-67↑, PCNA↓, GutMicro↑, *Inflam↓, *cardioP↑, *ROS↓,
5422- ASTX,    Improved intestinal absorption and oral bioavailability of astaxanthin using poly (ethylene glycol)-graft-chitosan nanoparticles: preparation, in vitro evaluation, and pharmacokinetics in rats
- in-vivo, Nor, NA
*antiOx↑, *AntiDiabetic↑, *toxicity∅, *BioAv↓, *BioAv↑,
5423- ASTX,    Pharmacokinetic Profile of Astaxanthin Nanoemulsion Using HPLC (High-Performance Liquid Chromatography) With Oral Routes
- in-vivo, Nor, NA
*BioAv↓, *antiOx↑, *BioAv↑, *Half-Life↝,
5424- ASTX,    Astaxanthin exerts an adjunctive anti-cancer effect through the modulation of gut microbiota and mucosal immunity
- in-vivo, Nor, NA
*GutMicro↑, AntiCan↑, eff↑, AntiTum↑, ChemoSen↑,
5425- ASTX,    Multiple roles of fucoxanthin and astaxanthin against Alzheimer's disease: Their pharmacological potential and therapeutic insights
- in-vivo, AD, NA
*neuroP↑, *antiOx↑, *Inflam↑, *AChE↓, *BACE/β-secretase↓, *MAOA↓, *Aβ↓, *memory↑, *MDA↓, *SOD↑, *NRF2↑, *HO-1↑, *NF-kB↓, *GSK‐3β↓, *ChAT↑, *iNOS↓, *ROS↓, *BBB↑,
147- ATG,  EGCG,  CUR,    Increased chemopreventive effect by combining arctigenin, green tea polyphenol and curcumin in prostate and breast cancer cells
- in-vitro, Pca, LNCaP - in-vitro, Pca, MCF7
Bax:Bcl2↑, NF-kB↓, PI3K/Akt↓, STAT3↓, chemoPv↑, TumCP↓, TumCCA↑, TumCMig↓,
5372- ATO,    Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
- Trial, APL, NA
Remission↑, OS↑, toxicity↓,
5373- ATO,    arsenic trioxide
- Human, APL, NA
Half-Life↝,
5375- ATO,    Improved Outcome with ATRA-Arsenic Trioxide Compared to ATRA-Chemotherapy in Non-High Risk Acute Promyelocytic Leukemia – Updated Results of the Italian-German APL0406 Trial on the Extended Final Series
- Trial, APL, NA
eff↑, OS↑,
5374- ATO,    A pharmacokinetic and safety study of oral arsenic trioxide in patients with acute promyelocytic leukemia
- Trial, APL, NA
toxicity↓, OS↑,
5454- ATV,    Interplay of mevalonate and Hippo pathways regulates RHAMM transcription via YAP to modulate breast cancer cell motility
- Review, BC, NA
HMG-CoA↓, HMGCR↓, TumCP↓, RadioS↑, CD44↓, P53↑,
5453- ATV,    Epidemiologic Analysis Along the Mevalonate Pathway Reveals Improved Cancer Survival in Patients Who Receive Statins Alone and in Combination With Bisphosphonates
- Trial, Var, NA
OS↑, eff↑, other↝,
5452- ATV,    Mevalonate pathway in pancreatic ductal adenocarcinoma: mechanisms driving metabolic and cellular plasticity
- Review, Var, NA
ChemoSen↑, HMG-CoA↓, EMT↓, Ferroptosis↑, Hif1a↓,
5451- ATV,    In vitro and in vivo anticancer effects of mevalonate pathway modulation on human cancer cells
- in-vitro, BC, MDA-MB-231 - in-vitro, GBM, U87MG - in-vitro, GBM, A172
TumAuto↑, CSCs↓, HMG-CoA↓, TumCP↓, tumCV↓, TumCCA↑, TumCG↓, HMGCR↓,
5450- ATV,    The Mevalonate Pathway in the Radiation Response of Cancer
- vitro+vivo, Var, NA
eff↑, RadioS↑,
5448- ATV,    Beyond cardiovascular health: The pharmacotherapeutic potential of statins in oncology
- Review, Var, NA
Apoptosis↑, TumAuto↑, TumCCA↑, BioAv↓, eff↑, HMGCR↓, LDL↓, cardioP↑, AntiTum↑, ChemoSen↑, RadioS↑, toxicity↓,
5447- ATV,    The Mevalonate Pathway, a Metabolic Target in Cancer Therapy
- Review, Var, NA
Risk↓, Dose↑, ChemoSen↑, chemoP↑, HMG-CoA↓, EMT↓, CSCs↓, HH↝, YAP/TEAD↝,
5446- ATV,    Targeting the Mevalonate Pathway in Cancer
- Review, Var, NA
EMT↓, HMG-CoA↓,
5445- ATV,    Atorvastatin
- NA, Nor, NA
*cardioP↑, *LDL↓, HMG-CoA↓, Half-Life↝, BioAv↓, Dose↝,
5449- ATV,    Pleiotropic effects of statins: A focus on cancer
- NA, Var, NA
lipid-P↓, TumCG↓, Apoptosis↑, ChemoSen↑, RAS↓, HMG-CoA↓, HMGCR↓, LDL↓, toxicity↓, Risk↓, P21↑, HDAC↓, Bcl-2↓, BAX↑, BIM↑, Casp↑, cl‑PARP↑, MMP↓, ROS↑, angioG↓, TumMeta↓, PTEN↑, eff↑, OS↑, Remission↑,
4982- ATV,    Inhibiting the mevalonate pathway with atorvastatin alters gut microbiota and has potential as an anti-cancer treatment for ovarian cancer
- in-vivo, Ovarian, NA
HMG-CoA↓, GutMicro↑,
4981- ATV,    Crosstalk between Statins and Cancer Prevention and Therapy: An Update
Apoptosis↑, selectivity↑, eff↑, HMG-CoA↓, *cardioP↑, OS↑, IL1β↓, IL6↓, IL8↓, TNF-α↓, TumAuto↑, Histones↝, ac‑H3↑, ac‑H4↑, HDAC↓,
4980- ATV,    A review of effects of atorvastatin in cancer therapy
- Review, Var, NA
HMG-CoA↓, TumCP↓, TumCMig↓,
4979- ATV,  Rad,    Short‐Term Statin Treatment Reduces, and Long‐Term Statin Treatment Abolishes, Chronic Vascular Injury by Radiation Therapy
- in-vivo, Nor, NA
radioP↑, radioP↑,
4978- ATV,  Rad,    Atorvastatin Sensitizes Breast and Lung Cancer Cells to Ionizing Radiation
- in-vitro, BC, A549
Apoptosis↑, RadioS↑, TumCP↓, ROS↑,
4988- ATV,  Dipy,    Repurposing of the Cardiovascular Drug Statin for the Treatment of Cancers: Efficacy of Statin–Dipyridamole Combination Treatment in Melanoma Cell Lines
- in-vivo, Melanoma, NA
HMGCR↓, SREBP2↑, SREBP2↓, AntiAg↑,

Showing Research Papers: 1051 to 1100 of 8263
Prev Page 22 of 166 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 8263

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 3,   Catalase↑, 1,   Ferroptosis↑, 2,   GPx↑, 1,   GPx4↓, 1,   lipid-P↓, 2,   MDA↓, 2,   NRF2↑, 1,   ROS↓, 3,   ROS↑, 3,   ROS⇅, 1,   ROS∅, 1,   SOD↑, 3,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

MMP↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

cMyc↓, 1,   Histones↝, 1,   HMG-CoA↓, 10,   LDL↓, 2,   PI3K/Akt↓, 1,   SREBP2↓, 1,   SREBP2↑, 1,  

Cell Death(tgid=5) ⓘ

Akt↓, 2,   Akt↑, 1,   Apoptosis↓, 1,   Apoptosis↑, 14,   BAX↑, 3,   BAX⇅, 1,   Bax:Bcl2↑, 1,   Bcl-2↓, 5,   BIM↑, 1,   Casp↑, 1,   Casp3↑, 3,   cl‑Casp3↑, 1,   Ferroptosis↑, 2,   MAPK↓, 1,   p27/CDKN1B↑, 1,   TumCD↑, 3,   YAP/TEAD↝, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

HER2/EBBR2↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

ac‑H3↑, 1,   ac‑H4↑, 1,   other↝, 1,   tumCV↓, 4,  

Autophagy & Lysosomes(tgid=9) ⓘ

TumAuto↑, 3,  

DNA Damage & Repair(tgid=10) ⓘ

DNAdam↑, 1,   P53↓, 1,   P53↑, 2,   cl‑PARP↑, 1,   PARP1↑, 1,   PCNA↓, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK1↑, 1,   CDK4↓, 1,   cycD1/CCND1↓, 2,   P21↑, 3,   TumCCA↑, 8,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

CD44↓, 1,   CSCs↓, 3,   EMT↓, 4,   ERK↓, 2,   p‑ERK↓, 1,   GSK‐3β↑, 1,   HDAC↓, 2,   HH↝, 1,   HMGCR↓, 5,   Nanog↓, 1,   OCT4↓, 1,   PI3K↓, 2,   PI3K↑, 1,   PTEN↑, 1,   RAS↓, 1,   STAT3↓, 2,   TumCG↓, 4,   TumCG↑, 1,  

Migration(tgid=13) ⓘ

AntiAg↑, 1,   E-cadherin↑, 1,   Ki-67↑, 1,   miR-200b↑, 1,   miR-29b↑, 2,   MMP1↓, 1,   MMP2↓, 2,   MMP9↓, 1,   MMPs↓, 2,   N-cadherin↓, 1,   TumCI↓, 2,   TumCMig↓, 6,   TumCP↓, 14,   TumCP↑, 1,   TumCP⇅, 1,   TumMeta↓, 3,   Zeb1↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 1,   EGFR↓, 1,   Hif1a↓, 1,   VEGF↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

IL1β↓, 1,   IL6↓, 1,   IL8↓, 1,   Inflam↓, 1,   NF-kB↓, 2,   PSA↓, 1,   TNF-α↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 2,   BioAv↑, 3,   ChemoSen↑, 8,   ChemoSen⇅, 1,   Dose↓, 1,   Dose↑, 2,   Dose⇅, 1,   Dose↝, 3,   eff↑, 10,   Half-Life↝, 2,   RadioS↑, 5,   selectivity↑, 4,  

Clinical Biomarkers(tgid=22) ⓘ

EGFR↓, 1,   GutMicro↑, 2,   HER2/EBBR2↓, 1,   IL6↓, 1,   Ki-67↑, 1,   PSA↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 5,   AntiTum↑, 4,   cardioP↑, 1,   chemoP↑, 4,   chemoPv↑, 2,   OS↑, 6,   Pain↓, 1,   radioP↑, 3,   Remission↑, 2,   Risk↓, 3,   toxicity↓, 4,  
Total Targets: 130

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 12,   HO-1↑, 1,   lipid-P↓, 1,   MDA↓, 2,   NRF2↑, 2,   ROS↓, 5,   SOD↑, 4,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

MMP↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

LDL↓, 1,  

Cell Death(tgid=5) ⓘ

Apoptosis↓, 1,   iNOS↓, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

ERK↓, 1,   GSK‐3β↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

NO↓, 1,  

Barriers & Transport(tgid=15) ⓘ

BBB↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

IFN-γ↓, 2,   IL6↓, 2,   IL8↓, 1,   Inflam↓, 5,   Inflam↑, 1,   NF-kB↓, 3,   PGE2↓, 1,   TNF-α↓, 2,  

Synaptic & Neurotransmission(tgid=18) ⓘ

AChE↓, 1,   BDNF↑, 1,   ChAT↑, 1,   MAOA↓, 1,  

Protein Aggregation(tgid=19) ⓘ

Aβ↓, 1,   BACE/β-secretase↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 4,   BioAv↑, 5,   BioAv↝, 2,   Dose↝, 1,   eff↑, 1,   Half-Life↝, 1,  

Clinical Biomarkers(tgid=22) ⓘ

GutMicro↑, 1,   IL6↓, 2,  

Functional Outcomes(tgid=23) ⓘ

AntiDiabetic↓, 1,   AntiDiabetic↑, 1,   AntiTum↑, 2,   cardioP↑, 4,   memory↑, 1,   neuroP↑, 4,   toxicity∅, 1,  
Total Targets: 44

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page